Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients

Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients

(2014) X.-F. Wang et al.   JOURNAL OF IMMUNOLOGY

Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma

(2009) Alvaro Lladser et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A systematic review of humoral immune responses against tumor antigens

(2009) Miriam Reuschenbach et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells

(2009) V. Francois et al.   CANCER RESEARCH

Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas

(2009) S. Attig et al.   CANCER RESEARCH

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer

(2009) Susan Feyerabend et al.   PROSTATE

TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis

(2008) Nele Müller-Hermelink et al.   CANCER CELL

Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens

(2008) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE